<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197078</url>
  </required_header>
  <id_info>
    <org_study_id>1218.163</org_study_id>
    <nct_id>NCT02197078</nct_id>
  </id_info>
  <brief_title>Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin</brief_title>
  <official_title>Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This protocol is for a series of comparative effectiveness and safety analyses within
      periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and
      other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety
      of health outcomes. The primary analysis will be conducted among patients without prior
      within-class medication use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular event (composite of coronary revascularization, hospitalization for acute coronary syndrome, ischemic and hemorrhagic stroke)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary revascularization</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization for acute coronary syndrome</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of end-stage renal disease</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure requiring dialysis</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">99999</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Glitazones</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Within-class comparators</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        T2DM patients aged 18 or older, initiating antidiabetic treatment after at least 6 months
        of continuous enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A dispensing of an oral hypoglycemic medication

          -  A diagnosis of type 2 diabetes mellitus (T2DM)

        Exclusion criteria:

          -  less than 18 years old

          -  missing or ambiguous age or sex information

          -  at least one diagnosis of type 1 diabetes mellitus

          -  less than 6 months enrolment in the database preceding the date of the first
             dispensing

          -  secondary diabetes

          -  history of cancer

          -  end-stage renal disease (ESRD)

          -  HIV

          -  organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>July 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
